Milestone Pharmaceuticals is trading 5.65% up at $0.87 on September 30, 2026; the reason for the gain remains unclear. - No clear company-specific catalyst has surfaced. Its latest identified announcement came September 24. - It reported enrolling the first Canadian participant in its Phase 3 AFib-RVR trial; that news predates the session and does not establish the reason for the gain. - Major indexes are higher, while healthcare is down; available evidence does not establish a broad-market or sector explanation.